Trial Profile

A phase I clinical study of IC-100

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IC 100 ZyVersa Therapeutics (Primary)
Indications Adult respiratory distress syndrome; Alzheimer's disease; Autoimmune disorders; Metabolic disorders; Neurodegenerative disorders
Focus Adverse reactions

27 Mar 2025 According to a ZyVersa Therapeutics media release, Investigational New Drug Application (IND) for IC 100 is anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweight subjects.
03 Jan 2024 According to a ZyVersa Therapeutics media release, the IC 100 preclinical program is nearing completion and IND submission is planned for the fourth quarter of 2024, with Phase 1 trial initiation expected shortly thereafter.
13 Jun 2023 According to a ZyVersa Therapeutics media release, the company expects file an IND to initiate a Phase 1 trial in early 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com